Valuation: argenx SE

Capitalization 47.19B 54.89B 44.2B 41.2B 76.1B 4,940B 82.77B 517B 200B 2,333B 206B 202B 8,531B P/E ratio 2025 *
50.1x
P/E ratio 2026 * 30.8x
Enterprise value 44.2B 51.42B 41.41B 38.6B 71.29B 4,628B 77.54B 484B 187B 2,186B 193B 189B 7,992B EV / Sales 2025 *
12.2x
EV / Sales 2026 * 8.53x
Free-Float
99.23%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.82%
1 week+1.66%
Current month+0.33%
1 month+5.34%
3 months+21.07%
6 months+52.90%
Current year+30.83%
More quotes
1 week 765
Extreme 765
800.4
1 month 735.6
Extreme 735.6
810
Current year 456.6
Extreme 456.6
810
1 year 456.6
Extreme 456.6
810
3 years 271
Extreme 271
810
5 years 201.4
Extreme 201.4
810
10 years 9.1
Extreme 9.1
810
More quotes
Manager TitleAgeSince
Chief Executive Officer 53 2008-07-14
Director of Finance/CFO 55 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Director/Board Member 53 2014-06-30
Chairman 67 2008-10-14
Director/Board Member 75 2015-05-12
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.82%+1.66%+34.14%+109.61% 54.89B
-0.51%-1.81%+170.56%+977.65% 43.51B
+0.90%-0.87%+63.71%+14.60% 38.12B
+0.26%-6.69%-20.93%-40.82% 23.14B
+1.08%+0.39%+31.35%-36.64% 19.5B
+0.98%+3.85%+73.37%-40.70% 17.25B
+0.24%+3.15%+87.49%+220.62% 14.68B
-2.66%+2.35%-1.24%+494.48% 14.12B
-3.09%+1.32%+134.63% - 13.78B
-1.52%-3.30%+79.93%+757.04% 13.11B
Average +0.30%-0.68%+65.30%+272.87% 25.21B
Weighted average by Cap. +0.76%-1.20%+68.57%+280.68%
See all sector performances

Financials

2025 *2026 *
Net sales 3.63B 4.22B 3.4B 3.17B 5.85B 380B 6.36B 39.73B 15.34B 179B 15.83B 15.49B 656B 5B 5.82B 4.69B 4.37B 8.07B 524B 8.78B 54.83B 21.17B 247B 21.85B 21.38B 905B
Net income 992M 1.15B 929M 866M 1.6B 104B 1.74B 10.87B 4.2B 49.06B 4.33B 4.24B 179B 1.77B 2.05B 1.65B 1.54B 2.85B 185B 3.1B 19.34B 7.47B 87.29B 7.71B 7.54B 319B
Net Debt -2.98B -3.47B -2.79B -2.6B -4.81B -312B -5.23B -32.68B -12.62B -147B -13.02B -12.74B -539B -4.49B -5.23B -4.21B -3.92B -7.25B -471B -7.88B -49.25B -19.02B -222B -19.63B -19.21B -813B
More financial data * Estimated data
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,599
More about the company
Date Price Change Volume
25-12-08 785.00 +1.82% 6,125
25-12-05 771.00 -2.68% 57,338
25-12-04 792.20 -0.85% 53,076
25-12-03 799.00 +2.25% 57,174
25-12-02 781.40 +1.19% 64,717

Real-time Euronext Bruxelles, December 08, 2025 at 08:10 am

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
771.00EUR
Average target price
790.28EUR
Spread / Average Target
+2.50%
Consensus

Quarterly revenue - Rate of surprise